US Patent Issued to Amgen on May 12 for "Formulations and dosages for administering a compound that inhibits MCL1 protein" (California Inventors)

ALEXANDRIA, Va., May 12 -- United States Patent no. 12,622,918, issued on May 12, was assigned to Amgen Inc. (Thousand Oaks, Calif.).

"Formulations and dosages for administering a compound that inhibits MCL1 protein" was invented by Ron C. Kelly (Westlake Village, Calif.), Michael T. Kennedy (Newbury Park, Calif.) and Stevedat K. La (Moorpark, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure is drawn to pharmaceutical formulations, aqueous solutions, and methods of treating cancer using the disclosed pharmaceutical formulations and aqueous solutions. The formulations and solutions comprise compounds of Formula I and may further comprise a cyclodextrin compound, such as hydroxyprop...